New diagnostic criteria for neurocysticercosis: Reliability and validity (original) (raw)

Abstract

The diagnosis of neurocysticercosis (NCC) remains problematic because of the heterogeneity of its clinical, immunological, and imaging characteristics. Our aim was to develop and assess a new set of diagnostic criteria for NCC, which might allow for the accurate detection of, and differentiation between, parenchymal and extraparenchymal disease. Methods: A group of Latin American NCC experts developed by consensus a new set of diagnostic criteria for NCC. A multicenter, retrospective study was then conducted to validate it. The reference standard for diagnosis of active NCC was the disappearance or reduction of cysts after anthelmintic treatment. In total, three pairs of independent neurologists blinded to the diagnosis evaluated 93 cases (with NCC) and 93 controls (without NCC) using the new diagnostic criteria. Mixed-effects logistic regression models were used to estimate sensitivity and specificity. Results: Inter-rater reliability (kappa) of diagnosis among evaluators was 0.60. For diagnosis of NCC versus no NCC, the new criteria had a sensitivity of 93.2% and specificity of 81.4%. For parenchymal NCC, the new criteria had a sensitivity of 89.8% and specificity of 80.7% and for extraparenchymal NCC, the new criteria had a sensitivity of 65.9% and specificity of 94.9%. Interpretation: These criteria have acceptable reliability and validity and could be a new tool for clinicians and researchers. An advantage of the new criteria is that they consider parasite location (ie, parenchymal or extraparenchymal), which is an important factor determining the clinical, immunological, and radiological presentation of the disease, and importantly, its treatment and prognosis.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (36)

  1. Carpio A. Neurocysticercosis: an update. Lancet Infect Dis 2002;2: 751-762.
  2. Fleury A, Sciutto E, Larralde C. Neurocysticercosis is still prevalent in Mexico. Salud Publica Mex 2012;54:632-636.
  3. Cantey PT, Coyle CM, Sorvillo FJ, et al. Neglected parasitic infec- tions in the United States: cysticercosis. Am J Trop Med Hyg 2014;90:805-809.
  4. Fabiani S, Bruschi F. Neurocysticercosis in Europe: still a public health concern not only for imported cases. Acta Trop 2013;128: 18-26.
  5. Winkler AS, Richter H. Landscape analysis: management of neuro- cysticercosis with an emphasis on low-and middle-income coun- tries. Commissioned by the World Health Organization; 2015. Available at: http://apps.who.int/iris/bitstream/10665/152896/1/ WHO_HTM_NTD_NZD_2015.05_eng.pdf. Accessed June 1, 2015.
  6. Carabin H, Ndimubanzi PC, Budke CM, et al. Clinical manifesta- tions associated with neurocysticercosis: a systematic review. PLoS Negl Trop Dis 2011;5:e1152.
  7. Garg RK. Diagnostic criteria for neurocysticercosis: some modifica- tions are needed for Indian patients. Neurol India 2004;52: 171-177.
  8. Del Brutto OH, Rajshekhar V, White AC, Jr., et al. Proposed diag- nostic criteria for neurocysticercosis. Neurology 2001;57:177-183.
  9. Machado Ldos R. The diagnosis of neurocysticercosis: a closed question? Arq Neuropsiquiatr 2010;68:1-2.
  10. Cardenas G, Jung H, Rios C, et al. Severe cysticercal meningitis: clinical and imaging characteristics. Am J Trop Med Hyg 2010;82: 121-125.
  11. Gabriel S, Blocher J, Dorny P, et al. Added value of antigen ELISA in the diagnosis of neurocysticercosis in resource poor settings. PLoS Negl Trop Dis 2012;6:e1851.
  12. Kelesidis T, Tsiodras S. Extraparenchymal neurocysticercosis in the United States. Am J Med Sci 2012;344:79-82.
  13. Carpio A, Fleury A, Hauser WA. Neurocysticercosis: five new things. Neurol Clin Pract 2013;3:118-125.
  14. Escobar A, Nieto D. Cysticercosis. In: Minkler J, ed. The Pathology of the Nervous System. New York: McGraw-Hill; 1972:2507-2515.
  15. Zee CS, Go JL, Kim PE, DiGiorgio CM. Imaging of neurocysticer- cosis. Neuroimaging Clin N Am 2000;10:391-407.
  16. Lucato LT, Guedes MS, Sato JR, et al. The role of conventional MR imaging sequences in the evaluation of neurocysticercosis: impact on characterization of the scolex and lesion burden. AJNR Am J Neuroradiol 2007;28:1501-1504.
  17. Robbani I, Razdan S, Pandita KK. Diagnosis of intraventricular cys- ticercosis by magnetic resonance imaging: improved detection with three-dimensional spoiled gradient recalled echo sequences. Australas Radiol 2004;48:237-239.
  18. Mont'Alverne Filho FE, Machado Ldos R, Lucato LT, et al. The role of 3D volumetric MR sequences in diagnosing intraventricular neurocysticercosis: preliminar results. Arq Neuropsiquiatr 2011;69: 74-78.
  19. Tsang VC, Brand JA, Boyer AE. An enzyme-linked immunoelectro- transfer blot assay and glycoprotein antigens for diagnosing human cysticercosis (Taenia solium). J Infect Dis 1989;159:50-59.
  20. Brandt JR, Geerts S, De Deken R, et al. A monoclonal antibody- based ELISA for the detection of circulating excretory-secretory antigens in Taenia saginata cysticercosis. Int J Parasitol 1992;22: 471-477.
  21. Michelet L, Fleury A, Sciutto E, et al. Human neurocysticercosis: comparison of different diagnostic tests using cerebrospinal fluid. J Clin Microbiol 2011; 49:195-200.
  22. Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005;46:470-472.
  23. Thurman DJ, Beghi E, Begley CE, et al. Standards for epidemio- logic studies and surveillance of epilepsy. Epilepsia 2011;52(suppl 7):S2-S26.
  24. Rekate HL. A contemporary definition and classification of hydro- cephalus. Semin Pediatr Neurol 2009;16:9-15.
  25. Fleury A, Carrillo-Mezo R, Flisser A, et al. Subarachnoid basal neu- rocysticercosis: a focus on the most severe form of the disease. Expert Rev Anti Infect Ther 2011;9:123-133.
  26. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 2003;326:41-44.
  27. Carpio A, Kelvin EA, Bagiella E, et al. Effects of albendazole treat- ment on neurocysticercosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry 2008;79:1050-1055.
  28. Flahault A, Cadilhac M, Thomas G. Sample size calculation should be performed for design accuracy in diagnostic test studies. J Clin Epidemiol 2005;58:859-862.
  29. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.
  30. Govindappa SS, Narayanan JP, Krishnamoorthy VM, et al. Improved detection of intraventricular cysticercal cysts with the use of three-dimensional constructive interference in steady state MR sequences. AJNR Am J Neuroradiol 2000;21:679-684.
  31. Abraham R, Livramento JA, Leite Cda C, et al. Neurocysticercosis: relationship between Taenia antigen levels in CSF and MRI. Arq Neuropsiquiatr 2010;68:7-11.
  32. Lalla RS, Garg RK, Malhotra HS, et al. Cytokines, MMP-2, and MMP-9 levels in patients with a solitary cysticercus granuloma. Neurol India 2015;63:190-196.
  33. Singh G, Rajshekhar V, Murthy JM, et al. A diagnostic and thera- peutic scheme for a solitary cysticercus granuloma. Neurology 2010;75:2236-2245.
  34. Marquez-Caraveo C, Gongora-Rivera F, Santos Zambrano J, et al. Pre-treatment with corticosteroids and a single cycle of high dose albendazole for subarachnoidal cysticercosis. J Neurol Neurosurg Psychiatry 2004;75:938-939.
  35. Gongora-Rivera F, Soto-Hernandez JL, Gonzalez Esquivel D, et al. Albendazole trial at 15 or 30 mg/kg/day for subarachnoid and intraventricular cysticercosis. Neurology 2006;66:436-438.
  36. Jung H, Cardenas G,Sciutto E, et al. Medical treatment for neuro- cysticercosis: drugs, indications and perspectives. Curr Top Med Chem 2008;8:424-433.